LumiraDx Limited (LMDX)
| Market Cap | n/a |
| Revenue (ttm) | 24.94M |
| Net Income (ttm) | n/a |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About LMDX
LumiraDx is a next-generation point of care, or POC, diagnostic company. We have developed and launched our LumiraDx Platform, or Platform, which is an integrated system comprised of a small, versatile POC instrument, or Instrument, precise, low-cost microfluidic test strips, and seamless, secure digital connectivity. We currently have four tests available on our Platform and a broad menu of tests in development. Our proprietary Platform is designed to simplify, scale down, and integrate multiple testing methodologies onto a single instrument a...
News
COVID-19 test maker LumiraDx files for a $100 million US IPO
LumiraDx, a UK-based provider of point-of-care diagnostics including COVID-19 tests, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
LumiraDx IPO Registration Document (S-1)
LumiraDx Limited has filed to go public with an IPO on the NASDAQ.
Hospital emergency departments to use rapid Covid-19 testing with results in 12 minutes
A new rapid test for Covid-19 can return results in just 12 minutes, Health Minister Robin Swann has said.
LumiraDx Receives Authorization by Switzerlandu00b4s Federal Office of Public Health Showing Excellent Positive Agree...
LumiraDx, the next generation point-of-care diagnostic company, announced today that it has received Switzerland Federal Office of Public...